Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Agenus Inc.NASDAQ: AGEN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns positive

Q1 FY2026 EBITDA was $54.48M, compared with -$10.37M a year earlier. Trailing-twelve-month EBITDA was $127.04M.

Context

  • EBITDA amounted to 54.5% of revenue in FY2025, down 43.5 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $127.28M (+104.7%) for the fiscal year ending Dec 2026, a slowdown from the +161.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$54.48M+807.4% QoQ
Last fiscal yearDec 2025
$62.19M+161.4% YoY
LTMMar 2026
$127.04M+256.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+625.3%+253.4%-371.8 pp
1 year+161.4%+104.7%-56.7 pp
3-year CAGR—+11.7%—
5-year CAGR+7.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
62.19M USD
Year-over-year change
+161.4%
4-year CAGR
+9.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 EBITDA of $127.04M is the highest of the 10 companies compared; the peer median is -$104.73M.
  • Its year-over-year change of +256.7% is the highest of 9, against a peer median of +15.6%.
  • EBITDA amounts to 102.6% of revenue for AGEN, versus a peer median of 874.0%.
AGEN Competitors Peer median
EBITDA for AGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$127.04M +256.7%—102.6%
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.79M ———
HURATuHURA Biosciences, Inc.LTM Mar 2026-$30.19M -68.1%——
SEERSeer, Inc.LTM Mar 2026-$64.35M +18.9%—427.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$81.94M +12.2%——
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M -226.0%—874.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$107.98M +49.6%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$108.82M +2.8%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$130.98M +37.9%——
Peer median (excluding AGEN) -$104.73M+15.6%—874.0%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.67M98.02M156.31M103.46M114.2M
Cost of Revenue182.08M197.26M237.68M156.01M80.36M
Gross Profit113.59M(99.24M)(81.37M)(52.55M)33.84M
Gross Margin38.4%-101.2%-52.1%-50.8%29.6%
Research & Development178.61M0234.57M155.53M0
Selling, General & Admin76.36M81.01M78.74M71.88M54.39M
Operating Expenses87.84M80.19M78.18M67.92M54.39M
Depreciation & Amortization6.79M6.95M13.59M13.34M10M
EBITDA43.78M(161.85M)(145.92M)(101.3M)62.19M
EBITDA Margin14.8%-165.1%-93.4%-97.9%54.5%
Operating Income25.75M(179.43M)(159.55M)(120.48M)(20.56M)
Operating Margin8.7%-183.0%-102.1%-116.4%-18.0%
Interest Income00000
Interest Expense65.72M61.86M97.93M117.63M55.27M
Other Income / Expenses(54.47M)(51.23M)(97.89M)(111.8M)17.47M
Income Before Tax(28.72M)(230.66M)(257.44M)(232.27M)(3.08M)
Pre-Tax Margin-9.7%-235.3%-164.7%-224.5%-2.7%
Income Tax Expense00000
Net Income(23.93M)(220.07M)(245.76M)(227.21M)115K
Net Margin-8.1%-224.5%-157.2%-219.6%0.1%
EPS (Basic)(2.11)(15.64)(13.75)(10.59)(0.00)
EPS (Diluted)(2.11)(15.64)(13.75)(10.59)(0.00)
Weighted Avg Shares11.45M14.09M17.89M21.47M29.73M
Weighted Avg Shares (Diluted)11.45M14.09M17.89M21.47M29.73M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.